MedTrace Logo

Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)

NCT05940324 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-04-24

No results posted yet for this study

Summary

The purpose of this study is to understand how ketamine works in the brain to bring about a reduction in OCD symptoms.

Conditions

  • Obsessive-Compulsive Disorder

Interventions

DRUG

Ketamine

Ketamine is an FDA-approved dissociative anesthetic.

DRUG

Naltrexone Pill

Naltrexone is an oral opioid antagonist approved by the Food and Drug Administration (FDA) to treat both alcohol use disorder (AUD) and opioid use disorder (OUD)

OTHER

Placebo pill

An oral inactive placebo pill will be administered to preserve the blinded nature of the study.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-24
Primary Completion
2028-11-30
Completion
2028-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05940324 on ClinicalTrials.gov